301 filings
Page 4 of 16
8-K
z8pfql 4clw
19 Apr 22
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
4:01pm
424B5
rizqyek3zoiz3a fb
18 Apr 22
Prospectus supplement for primary offering
9:15am
424B5
lycor8ew
15 Apr 22
Prospectus supplement for primary offering
5:02pm
424B5
5gbqbqaxdzu 2up1djg
13 Apr 22
Prospectus supplement for primary offering
5:15pm
8-K
0snj ra80
13 Apr 22
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
5:09pm
8-K
q8h m14ym9vkt627q
14 Mar 22
Departure of Directors or Certain Officers
6:05am
8-K
zdozm1zysrvn4zd6cl
10 Mar 22
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
x74pd8 tk7kc8
18 Jan 22
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology
4:19pm
8-K
zvniiaalo7t4bm5r
14 Dec 21
Regulation FD Disclosure
4:30pm
8-K
wrtw1rmmlc9m9rjxg
8 Dec 21
Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution
8:05am
8-K
y02l3k
9 Nov 21
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:37pm
8-K
libmimnz
4 Nov 21
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
8:05am
8-K
ogxoayt w8e7
27 Oct 21
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe
8:05am
8-K
25a7p
7 Oct 21
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
8:05am
8-K
4ynx0r
20 Sep 21
Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy
11:40am
8-K
dwdmowca
10 Aug 21
Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update
5:12pm